Regeneron Pharmaceuticals Reports Q3 2025 Revenue of $3.754 Billion and Net Income of $1.460 Billion

Regeneron Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $3.754 billion, a slight increase from $3.721 billion in the same period last year. The company's net income for the quarter was $1.460 billion, or $13.62 per diluted share, compared to $1.341 billion, or $11.54 per diluted share, in the prior year. For the nine months ending September 30, 2025, total revenues reached $10.459 billion, up from $10.413 billion, while net income increased to $3.660 billion from $3.495 billion in the same period of 2024.

The company experienced a notable decline in net product sales, which totaled $1.588 billion for the third quarter, down from $1.946 billion a year earlier. This decrease was primarily attributed to lower sales volumes of EYLEA, which faced competitive pressures and a transition of patients to EYLEA HD. In contrast, collaboration revenue saw a significant increase, rising to $1.968 billion from $1.660 billion, largely driven by higher profits from the commercialization of Dupixent and Kevzara in collaboration with Sanofi.

Regeneron has made strategic moves to enhance its product pipeline, including an $80 million upfront payment for a license agreement with Hansoh Pharmaceuticals for a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical development. The company also purchased an FDA Rare Pediatric Disease Priority Review Voucher for $155 million. These investments reflect Regeneron's commitment to expanding its therapeutic offerings and addressing unmet medical needs.

Operationally, Regeneron reported an increase in research and development expenses, which rose to $1.475 billion for the third quarter, compared to $1.272 billion in the same period last year. The company’s average headcount increased to 15,301, up from 14,642 a year earlier, indicating a focus on expanding its workforce to support ongoing and future projects. The company also noted a gross margin on net product sales of 82% for the quarter, down from 87% in the previous year, attributed to increased manufacturing costs and amortization expenses.

Looking ahead, Regeneron anticipates continued fluctuations in its financial performance, influenced by the commercialization of its products, ongoing research and development activities, and the impact of competitive pressures in the market. The company remains focused on advancing its pipeline and expects to incur substantial expenses related to these efforts. Additionally, Regeneron plans to maintain its share repurchase program, with $2.156 billion remaining available for future buybacks, and has declared a quarterly cash dividend of $0.88 per share, reflecting its commitment to returning value to shareholders.